Glenmark to launch generic drug to treat metabolic acidosis in US

Glenmark Pharmaceuticals is set to launch an 8.4 per cent Sodium Bicarbonate Injection in the United States. This generic medication treats high acid levels in the body. The company expects to begin distribution this month. The drug is therapeutically equivalent to Abbott Laboratories' product. This move follows significant annual sales for the medication in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/niSgEa2
via IFTTT